ABVC News and Press, ABVC BioPharma Inc. From 06/03/25

Silicon Valley, CA - ( NewMediaWire ) - June 03, 2025 - – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that its Board ...

2025-05-22 16:12:55 ET More on ABVC BioPharma Financial information for ABVC BioPharma Read the full article on Seeking Alpha For further details see: ABVC BioPharma announces $100M mixed shelf offering

Scor SE ADR (SCRYY) is expected to report $0.07 for Q1 2025 ATA Creativity Global (AACG) is expected to report for Q1 2025 Codere Online Luxembourg S.A. (CDRO) is expected to report $0.05 for Q1 2025 Capital Properties, Inc. - Class A (CPTP) is expected to report for Q1 2025 Sika ...

SILICON VALLEY, CA - May 14, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system (CNS), ophthalmology, and oncology/hematology indications, today announced that it has received of...

2025-05-12 14:20:56 ET GD Culture Group Climbs 11% on $300M Crypto-Focused Funding Commitment Shares of GD Culture Group Limited (NASDAQ: GDC ) jumped over 11%, fueling the PRISM Emerging AdTech & Media Index , after the company announced a $300 million equity facility t...

SILICON VALLEY, CA - May 9, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system (CNS), ophthalmology, and oncology/hematology indications, today announced that the Japan Patent Of...

SILICON VALLEY, CA - May 1, 2025 ( NEWMEDIAWIRE ) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system, oncology, and ophthalmology indications, today announced its financial results for the first quarter...

 Revenue Surges 234%, Expenses Down 21%, EPS Improves 77%, with Over $18.3 Million Licensing Incomes Available SILICON VALLEY, CA - April 16, 2025 ( NEWMEDIAWIRE ) -  ABVC BioPharma, Inc.  (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatment...

 Revenue Surges 234%, Expenses Down 21%, EPS Improves 77%, with Over $18.3 Million Licensing Incomes Available SILICON VALLEY, CA - April 15, 2025 ( NEWMEDIAWIRE ) -  ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ...

2025-04-06 18:49:23 ET ABVC BioPharma, Inc. (ABVC) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 4.43%. The average open to low on the day of earnings was -4.95%. The average open to c...